Additionally, Mertens-Talcott et al. observed an oncogenic role of miR-27a in breast cancer, where it increased the percentage of breast cancer cells in the G2-M phase by targeting the Myt-1 gene [28]. This evidence concerns the gene MYT1 and breast carcinoma.